More recently, phase III trials have unveiled that the combined administration of MEK and RAF inhibitors significantly improves all of the parameters of clinical efficacy [137,138], which has led to FDA approving the use of trametinib/dabrafenib [136], cobimetinib/vemurafenib [139] and encorafenib/binimetinib [140] as the standard treatment for BRAF-mutant melanoma. This evidence concerns the gene MAP2K7 and melanoma.